Immusorba TR and PH.
Immusorba TR (IM-TR) and PH (IM-PH) were developed as adsorbents with non-biological materials as affinity ligands to remove pathogenic autoantibodies. The adsorbents of IM-TR and IM-PH are polyvinyl alcohol gel immobilized with tryptophan and phenylalanine as ligand, respectively. IM-TR is clinically applied for treatment of autoimmune neurological diseases such as myasthenia gravis and Guillain-Barre syndrome. IM-PH is used for not only neurological diseases such as GBS and multiple sclerosis but also collagen diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). As many autoantibodies with different specificities have been found to have similar affinities to the ligand of Immusorba, it is expected that Immusorba will be applied to more diseases and contribute to the clarification of the mechanisms of the development of diseases by the identification of adsorbed unknown pathogenic substances with Immusorba.
Hirata
Noriko
N
Development and Scientific Affairs Department, Asahi Medical Co., Tokyo, Japan. hirata.nb@om.asahi-kasei.co.jp
Kuriyama
Toshiji
T
Yamawaki
Naokuni
N
D000042:Absorption; D000109:Acetylcholine / Q000097:blood; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D001323:Autoantibodies / Q000276:immunology; D001672:Biocompatible Materials; D002986:Clinical Trials as Topic; D004867:Equipment Design; D004869:Equipment Safety; D020275:Guillain-Barre Syndrome / Q000628:therapy; D006801:Humans; D007163:Immunosorbent Techniques / Q000295:instrumentation*; D007164:Immunosorbents / Q000737:chemistry / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000628:therapy; D009157:Myasthenia Gravis / Q000628:therapy; D010649:Phenylalanine / Q000737:chemistry; D012680:Sensitivity and Specificity; D014364:Tryptophan / Q000737:chemistry*
D001323:Autoantibodies; D001672:Biocompatible Materials; D007164:Immunosorbents; D010649:Phenylalanine; D014364:Tryptophan; D000109:Acetylcholine